Skip to content
Open access

CXCR4-enriched B cells foster immunosuppression and gastric cancer progression in male mice via the adenosine-IL-10 axis.

Oct 2026 · Cellular and Molecular Gastroenterology and Hepatology · pp. 101917 · 0 citations
Medicine

TL;DR

This study uncovers a novel mechanism that CXCR4-enriched B cells in gastric tumor tissues suppress T cell immunity via adenosine-mediated IL-10 production, which may contribute to tumor immune escape and disease progression of GC.

Abstract

Background

&

Aims

B cells are one major component of immune cells infiltrated in human solid tumors. However, the role of tumor-infiltrating B cells in mediating disease progression of human gastric cancer (GC) remains elusive.

Methods

Flow cytometry, immunohistochemistry and immunofluorescence were performed to analyze the prevalence, phenotypic and functional features of B cells in different samples of GC patients. B cells and T cells were purified and cultured ex vivo for regulation and functional assays. Tumor responses to B cell deficiency or adoptively transferred IL10 knockout B cells or blockade of CXCR4 or CD73 were measured in an in vivo syngeneic male mouse model.

Results

GC patients showed a significantly increased B cell enrichment in the tumor tissues during disease progression. The accumulation of B cells in the tumor tissues was mediated by the CXCL12/CXCR4 chemotactic axis. Although a similar phenotypic feature of B cells was shown between tumor and non-tumor tissues, tumor-infiltrating B cells effectively suppressed T cell immunity and accelerated tumor growth via IL-10 ex vivo and in vivo. In addition, tumor-associated adenosine could promote the production of IL-10 by B cells, and inhibiting the rate limiting enzyme CD73 for adenosine production in vivo significantly suppressed IL-10 production of tumor-infiltrating B cells and attenuated GC growth.

Conclusions

Our study uncovers a novel mechanism that CXCR4-enriched B cells in gastric tumor tissues suppress T cell immunity via adenosine-mediated IL-10 production, which may contribute to tumor immune escape and disease progression of GC.

Read PDF

Similar papers

Open access Sep 2026

Dynamic regulation of hypoxia-associated regulatory CD39+CD73+ and IL35+ B cells in pancreatic cancer

B cells can suppress anti-tumor T cell responses, representing a potential mechanism of resistance to immunotherapy. Multiple Breg subsets have been described in humans and mice. Bregs inhibit anti-tumor immunity through cytokine secretion, immune checkpoint expression, and potentially adenosine generation, which colle...

Hannah R. Hall, Jeffrey Song, N. Kren et al. · 0 citations
Sep 2026

Abstract IA005: Determinants of B cell fate and function in cancer

Effector B cell responses in solid malignancies are associated favorable response to immunotherapy. B cells can amplify anti-tumor immune responses via antibody production, antigen presentation, and pro-inflammatory cytokine release; yet B cells in cancer patients and tumor-bearing mice often fail to support these fu...

Y. Pylayeva-Gupta · 0 citations
Sep 2026

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immunotherapy because of its immunosuppressive, T-cell–excluded microenvironment. Immune checkpoint blockade, alone or with chemotherapy, has shown limited efficacy, likely due to redundant suppressive pathways. CAF-derived CXCL12 acting throug...

I. Pellicciotta, G. Manji, A. Raufi et al. · 0 citations
Open access Sep 2026

Complement C5a Fosters Tumor-promoting Immunity by Recruiting regulatory T cells in hepatocellular carcinoma.

Findings reveal that cancer cell-derived anaphylatoxin C5a plays a pivotal role in promoting an inhibitory TIME in liver tumor tissues and blocking the C5a/C5ar1 axis in combination with immune checkpoint inhibitors could represent a promising strategy for treating HCC.

Run Huang, Tian-Hao Chu, Guiqi Zhu et al. · 0 citations
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Open access Oct 2026

Regulatory T cells in ovarian cancer

The paradox of immune resistance in High-Grade Serous Carcinoma (HGSC) of the ovary, despite high immune cell infiltration, is caused by a complex, multi-layered immunosuppressive tumor microenvironment (TME) that disables and excludes effector immune cells. This is resolved by the aggressive co-option of immunosuppres...

C. Bose · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.